Association between health-service use and multiplex genetic testing

[1]  N. Schork,et al.  Effect of direct-to-consumer genomewide profiling to assess disease risk. , 2011, The New England journal of medicine.

[2]  Laurie Udesky,et al.  The ethics of direct-to-consumer genetic testing , 2010, The Lancet.

[3]  James P Evans,et al.  Preparing for a consumer-driven genomic age. , 2010, The New England journal of medicine.

[4]  M. Murray,et al.  Risks of presymptomatic direct-to-consumer genetic testing. , 2010, The New England journal of medicine.

[5]  F. Collins,et al.  Genomic medicine--an updated primer. , 2010, The New England journal of medicine.

[6]  Alexander A. Morgan,et al.  Clinical assessment incorporating a personal genome , 2010, The Lancet.

[7]  C. McBride,et al.  Participation in Genetic Testing Research Varies by Social Group , 2010, Public Health Genomics.

[8]  C. Shuman,et al.  Direct‐to‐consumer genetic testing: good, bad or benign? , 2010, Clinical genetics.

[9]  S. Kardia,et al.  Considerations for Designing a Prototype Genetic Test for Use in Translational Research , 2009, Public Health Genomics.

[10]  Andreas D. Baxevanis,et al.  Characteristics of users of online personalized genomic risk assessments: Implications for physician-patient interactions , 2009, Genetics in Medicine.

[11]  Tao Wang,et al.  Social Networkers' Attitudes Toward Direct-to-Consumer Personal Genome Testing , 2009, The American journal of bioethics : AJOB.

[12]  Amy L. McGuire,et al.  An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. , 2008, JAMA.

[13]  C. McBride,et al.  Putting science over supposition in the arena of personalized genomics , 2008, Nature Genetics.

[14]  M. McCarthy,et al.  Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.

[15]  Francis S Collins,et al.  The genome gets personal--almost. , 2008, JAMA.

[16]  Paul G Shekelle,et al.  Delivery of genomic medicine for common chronic adult diseases: a systematic review. , 2008, JAMA.

[17]  S. Grambow,et al.  Behind closed doors: management of patient expectations in primary care practices. , 2007, Archives of internal medicine.

[18]  Esben Budtz-Jørgensen,et al.  Confounder selection in environmental epidemiology: assessment of health effects of prenatal mercury exposure. , 2007, Annals of epidemiology.

[19]  H. Stefánsson,et al.  Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes , 2006, Nature Genetics.

[20]  P J Talmud,et al.  Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects , 2005, Circulation.

[21]  M. Loh,et al.  Polymorphisms of the insertion / deletion ACE and M235T AGT genes and hypertension: surprising new findings and meta-analysis of data , 2005, BMC nephrology.

[22]  S. Kono,et al.  Methylenetetrahydrofolate reductase polymorphism, alcohol intake, and risks of colon and rectal cancers in Korea. , 2004, Cancer letters.

[23]  M. Daly,et al.  Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes. , 2004, Diabetes.

[24]  J. Witteman,et al.  The -514 C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. , 2004, The Journal of clinical endocrinology and metabolism.

[25]  S. Humphries,et al.  Endothelial Nitric Oxide Synthase Genotype and Ischemic Heart Disease: Meta-Analysis of 26 Studies Involving 23028 Subjects , 2004, Circulation.

[26]  A. Nordström,et al.  Interleukin-6 promoter polymorphism is associated with bone quality assessed by calcaneus ultrasound and previous fractures in a cohort of 75-year-old women , 2004, Osteoporosis International.

[27]  J. Manson,et al.  Are variants in the CAPN10 gene related to risk of type 2 diabetes? A quantitative assessment of population and family-based association studies. , 2004, American journal of human genetics.

[28]  R. Kravitz,et al.  How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[29]  R. Peters,et al.  Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis , 2003, Human Genetics.

[30]  R. Kravitz,et al.  Direct observation of requests for clinical services in office practice: what do patients want and do they get it? , 2003, Archives of internal medicine.

[31]  S. Ralston,et al.  Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. , 2003, Bone.

[32]  P. Dayer,et al.  Point: myeloperoxidase -463G --> a polymorphism and lung cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  J. Ioannidis,et al.  Association of Polymorphisms of the Estrogen Receptor α Gene With Bone Mineral Density and Fracture Risk in Women: A Meta‐Analysis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  E S Lander,et al.  The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. , 2000, Nature genetics.

[35]  D. Duffy,et al.  Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? , 2000, American journal of human genetics.

[36]  S. Greenland,et al.  Simulation study of confounder-selection strategies. , 1993, American journal of epidemiology.